Dr. Tony Tsai, MD

Dr. Tsai practices at Retinal Consultants Medical Group in Sacramento, California.

Dr. Tsai's NPI, 1548294101, was assigned on July 10, 2006. Dr. Tsai graduated from WashU Medicine in 1998. Dr. Tsai holds California license A96629.

Dr. Tsai's primary practice is Retinal Consultants Medical Group, at 3 Park Center Dr, Sacramento, CA 95825 in Sacramento County. The practice phone is (916) 596-2027.

Dr. Tsai's primary practice is Retinal Consultants Medical Group in Sacramento, California. Dr. Tsai is also affiliated with Dignity Health - Mercy General Hospital. Dmand AI also links Dr. Tsai to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tsai practices, 2 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Tsai's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Tsai is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Tsai's licenses on file in 2 states: California and Maryland.

Dmand AI lists age-related macular degeneration, cataract, dry eye, eyelid inflammation, glaucoma, hypertensive retinopathy, inflammation of iris and laser destruction of retinal or choroid lesions among the conditions Dr. Tsai treats.

CMS data shows 59,438 Medicare services from Dr. Tsai across 32 procedure codes in 2024, for 1,494 Medicare patients. Medicare paid $3,769,610 for them.

CMS counts 1,494 Medicare patients who saw Dr. Tsai in 2024. The largest group is 65 to 74, with 559 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 1.45, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Tsai's median patient age at 71, with 55% women.

In 2024, Dr. Tsai wrote 566 Medicare Part D claims for 234 patients. 67% of them were for generic drugs. CMS names the drug for 482 of them, across 8 drugs with 11 or more claims each, at $12,724 in total drug cost. In 2023, CMS named 466 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Tsai for performance year 2024, reported as part of a group. Dr. Tsai accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 18 papers to Dr. Tsai, published from 2014 to 2025. 2016 was the busiest year, with 2. The most frequent topics are Zebrafish, Zebrafish Proteins and Actomyosin. Dr. Tsai's most frequent co-authors are Thomas M. Aaberg, MD, Thomas Marshall Aaberg, MD and Dan S. Gombos, MD.

Dmand AI links Dr. Tsai to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Uveal Melanoma and Uveal Neoplasms.

CMS Open Payments shows 112 general payments to Dr. Tsai from 24 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Genentech, Inc. paid the most, $1,846.

Dmand AI lists 1 award for Dr. Tsai.

Dr. Tsai graduated from WashU Medicine in 1998. Dr. Tsai is a member of AAO, AMA and ASRS.

Dr. Tsai is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.